Nucleoside diphosphate kinase associated with rat pancreatic membranes regulates CCK receptor affinity.
We have previously demonstrated in permeabilized rat pancreatic acini that the existence of two affinity states of the pancreatic cholecystokinin (CCK) receptor seen in intact cells depends on the presence of ATP. In the present study, we demonstrate that this effect of ATP is mediated by the enzyme nucleoside diphosphate kinase (NDPK). Northern blot hybridization analysis demonstrated NDPK mRNA in pancreas. Furthermore, pancreatic membranes possessed NDPK activity, which transferred high-energy phosphate groups to [8-3H]GDP. This enzyme also utilized UTP and ITP as a source of gamma-phosphate for GTP formation while guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) was formed in the presence of adenosine 5'-O-(3-thiotriphosphate) (ATP gamma S). However, adenylyl (beta, gamma-methylene)-diphosphate (AMP-PCP) did not serve as a substrate for NDPK. Analysis of 125I-Bolton-Hunter-labeled CCK octapeptide ([125I]BH-CCK-8) binding data in the absence of nucleotides was consistent with a single affinity state with dissociation constant (Kd) equal to 80 pM and maximal binding equal to 50.8 fmol/mg. ATP, UTP, ITP, ATP gamma S, and GTP gamma S all induced two CCK binding affinity states, which in the presence of 1 mM ATP were Kd = 74 pM for high-affinity sites and Kd = 4.3 nM for low-affinity sites: AMP-PCP did not induce two affinity states. GDP at 10 microM had no effect on CCK binding but potentiated the effect of ATP. GTP gamma S, in addition to inducing high- and low-affinity states, also elicited a significant concentration-dependent reduction in the total number of measurable CCK receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Physiology, University of Michigan, Ann Arbor 48109-0622.
G T
GT
Blevins
E M
EM
van de Westerlo
J A
JA
Williams
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D001570:Benzodiazepinones / Q000378:metabolism; D001667:Binding, Competitive / Q000187:drug effects; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000378:metabolism; D020109:Devazepide; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D008566:Membranes / Q000378:metabolism; D009701:Nucleoside-Diphosphate Kinase / Q000378:metabolism*; D009711:Nucleotides / Q000494:pharmacology; D010179:Pancreas / Q000378:metabolism*; D047428:Protein Kinase Inhibitors; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000378:metabolism*; D012844:Sincalide / Q000031:analogs & derivatives / Q000378:metabolism; D013379:Substrate Specificity; D013388:Succinimides / Q000378:metabolism; D013997:Time Factors
D001570:Benzodiazepinones; C044758:Bolton Hunter-cholecystokinin octapeptide; D009711:Nucleotides; D047428:Protein Kinase Inhibitors; D011949:Receptors, Cholecystokinin; D013388:Succinimides; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D000255:Adenosine Triphosphate; D002766:Cholecystokinin; D009701:Nucleoside-Diphosphate Kinase; D020109:Devazepide; D012844:Sincalide